Alternative splicing and mutation status of CHEK2 in stage III breast cancer. - Wikidata - wikimedia - TriplyDB

Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

http://www.wikidata.org/entity/Q48173616

about

The CHEK2 gene and inherited breast cancer susceptibility Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response Alteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes.Fusion of the tumor-suppressor gene CHEK2 and the gene for the regulatory subunit B of protein phosphatase 2 PPP2R2A in childhood teratoma Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications.Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma.Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.CHEK2 contribution to hereditary breast cancer in non-BRCA families Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.Heterozygous screen in Saccharomyces cerevisiae identifies dosage-sensitive genes that affect chromosome stability.Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis.Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer Prevalence of the CHEK2 R95* germline mutation Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.RNA splicing: a new player in the DNA damage response MicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2.CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.Centrosomal Chk2 in DNA damage responses and cell cycle progression.Evidence of the modulation of mRNA splicing fidelity in humans by oxidative stress and p53.Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif.High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.An extensive program of periodic alternative splicing linked to cell cycle progression.A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing.Adjuvant treatment: the contribution of expression microarrays.Chk2 oligomerization studied by phosphopeptide ligation: implications for regulation and phosphodependent interactions.Restoration of fragile histidine triad expression restores Chk2 activity in response to ionizing radiation in oral squamous cell carcinoma cells.Malfunctioning DNA damage response (DDR) leads to the degeneration of nigro-striatal pathway in mouse brain.TP53 and additional pathways in therapy resistance.Genetic and epigenetic analyses guided by high resolution whole-genome SNP array reveals a possible role of in Wilms tumour susceptibility

P2860

Q28265315-D7B83592-D2EA-43C4-ACDB-4A14EA3E2970 Q28395484-86BC6893-10BC-484F-85D0-EE76B26F53F1 Q28396027-480F7658-CD49-40D0-A6AB-2E508E3A22B3 Q28473504-EC882E1A-DBF7-48E3-A5FA-676D91AC3E7B Q34519722-2E7DCDDB-74CF-49E2-BD2F-7BBBE903D682 Q34542508-4FE3FA53-834F-4E36-B152-A8CF931FAC04 Q35070054-358EB83A-3989-47C4-843B-9D42E6166CB5 Q35683548-2A8A8A2E-2B04-421A-A8BF-BD51C0AC05E3 Q35763880-24272E8A-0E1E-431F-B03A-A183BA31BFE3 Q35836700-90BAEC1D-502A-4C9A-B722-8BAA7F7D0086 Q35889614-28824931-BB0D-4F41-80A3-BC6AEBF33D48 Q36245541-D405A238-02F3-44AB-9C1C-8A46F41B1F12 Q36515688-5FCB0ED3-5536-4A8C-8BCB-8ACCADFD3C21 Q36973287-3F6A7A87-EC37-4061-A139-F1171D4B3C61 Q37039810-F63BBB19-704B-40F9-91C3-E1C23AFAA202 Q37253985-CAC09036-706B-4F52-B130-984A24DFF0BD Q37291784-D62CF279-BE35-4A06-92B8-FBE4CC7D30F5 Q38087850-8E4A6796-0300-43F8-B255-B8E6112C0328 Q38155497-6FF24B77-BE00-46FA-A267-B3AA09F153D3 Q38899676-5B8DDC46-9C04-49A1-87D1-B185D4001076 Q39505275-0AC29463-90B9-4057-AB39-F01803DE2E4B Q39676551-411C5831-C7D0-473F-BB57-F3DB3178A5FB Q40039529-B9EC894E-9355-44CB-A2FD-D9B2AE249236 Q40366552-E6F18A8B-F650-4CA5-AB8D-BBC28D4088EE Q41812715-0F92EA75-6D79-4577-9DBB-B0D60B087E65 Q41899812-44CF6D07-F0D9-4FE5-B872-6C642E56E4F2 Q42754639-0672DBF8-419A-4576-A3D6-EF3F157F0BCC Q42815399-9261BA53-138F-45BA-8545-E43563E80909 Q45788484-B81070C9-D2D9-4A07-A829-EF3CC8812915 Q46299925-EC9E1AB3-6793-44A7-AF2D-BD765957F0AD Q46826896-34AB2F00-685D-4D47-ABD7-836EB708068C Q48895419-D3E1EB90-77F8-432F-BDA3-5506123CC574 Q50104546-9AD4D5EB-FECD-40A4-8472-1353E97911E7 Q57821557-56C148DA-E977-4131-805A-12B10F58BEAC

P2860

Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

http://www.wikidata.org/entity/Q48173616

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

@en

Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

@nl

type

label

Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

@en

Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

@nl

prefLabel

Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

@en

Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

@nl

P1433

Q48173616-9C0BEF76-C2D3-4AD6-8E62-4EB2940E6AC2

P1476

Q48173616-52363C39-FEE9-4D10-9BFE-0FD7247113FF

P2093

Q48173616-16858B18-9325-44CF-A72F-24185DC2BB18

Q48173616-38C000A1-9CF6-4973-9467-2AE0AF88BAAE

Q48173616-B9A9E3C3-D0B0-4913-BC64-54F901798ECE

P2860

Q48173616-011CC758-76E3-4749-8419-6D41683CA894

Q48173616-5119A30F-60B2-41D8-AA07-AB2C71E2233E

Q48173616-84F5674B-59C1-4385-ACF6-D32D08F577A0

Q48173616-8F2D526C-1ECC-4E0D-BF17-83B8788E349A

Q48173616-B9FD9BF2-5DF4-43A6-BC95-C8B8FAC12FA3

Q48173616-BEEA2D7F-A167-4609-85A7-CB09F44AF552

Q48173616-C0FF83E8-D797-49EC-A289-3FDCD6A8CB85

Q48173616-CF794DA0-2C3F-4B74-B08F-250EA1955C2E

Q48173616-D974B037-791C-45C7-B972-610D3D45D88B

Q48173616-E298227A-E37A-479A-8CAF-CE4A9A5B3E1E

P2888

Q48173616-015060F5-9FC5-48E8-B7ED-163F8AA59F91

P304

Q48173616-A639A8FE-E986-4C71-B46B-A9F606AD1661

P31

Q48173616-20002468-D57F-4306-9BED-278F5B960ED5

P356

Q48173616-57E1A7DD-AE79-402D-8B1A-06B915F35E01

P407

Q48173616-3BB28C95-4BD0-4708-ACD7-087EBB60875E

P433

Q48173616-C07B6240-0969-43D3-9D3E-E6BA13CC5E8F

P478

Q48173616-E8C04156-E53F-44A8-8DF4-B040E844D6F9

P50

Q48173616-102F08AC-016E-46CC-934D-90807C3024DE

Q48173616-21C8C0BC-42F7-4972-B03F-F3E1B79518C1

Q48173616-2B7AFBCF-0674-48E4-855A-E3514E5CB2FA

Q48173616-89D147C2-5401-440B-9A54-7277C3887419

Q48173616-9A3915B6-00BC-4278-BF28-3F42BF121F13

Q48173616-F3A325D4-4B5C-4A8B-BDAC-24E01601E6E5

P577

Q48173616-0344AA48-8FE1-4E6B-8618-AFC81E642623

P5875

Q48173616-51AE3094-1CAF-4473-97AC-21878D5F5829

P698

Q48173616-BA1D33DD-03DA-4D16-B846-E6521D980845

P356

P1433

P1476

Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

@en

P2093

Jacob Falck

http://www.w3.org/2001/XMLSchema#string

Johan Richard Lillehaug

http://www.w3.org/2001/XMLSchema#string

Vidar Staalesen

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain

p73 is over-expressed in vulval cancer principally as the Delta 2 isoform

The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype.

CHK2 kinase--a busy messenger.

Targeting the checkpoint kinases: chemosensitization versus chemoprotection.

Mutation analysis of the CHK2 gene in families with hereditary breast cancer.

Analysis of CHK2 in vulval neoplasia

CHEK2 variants associate with hereditary prostate cancer.

A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Mutations in CHEK2 associated with prostate cancer risk.

P2888

P304

8535-8544

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1207928

http://www.w3.org/2001/XMLSchema#string

P407

P433

52

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Anne-Lise Børresen-Dale

Per Eystein Lønning

Jiřina Bártková

Stephanie Geisler

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8352461

http://www.w3.org/2001/XMLSchema#string

P698

15361853

http://www.w3.org/2001/XMLSchema#string